Fig. 9From: A novel immunogenic cell death-related classification indicates the immune landscape and predicts clinical outcome and treatment response in acute myeloid leukemiaDifferences in chemotherapy sensitivity and immunotherapy response between high- and low-risk groups. A–C Sensitivity prediction of cytarabine, doxorubicin, and midostaurin for AML in high- and low-risk groups. D Chemotherapeutic agents with differential sensitivity between risk groups in the Beat AML cohort. E, F The differences in risk scores of patients with or without response to induction chemotherapy and the proportion differences between risk groups. G Prediction of the proportion of patients with or without response to immunotherapy in different risk score groups. H Prediction of response to anti-PD-1 and anti-CTAL4 immunotherapy in different risk score groupsBack to article page